Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, are promising therapies for diabetes and obesity due to their appetite-suppressing effects and weight loss. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.